EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients

Ishtiaq Ahmad, Hamidullah

Journal of the Pakistan Medical Association · 2024

DOI: 10.47391/jpma.10480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pakistan Medical Association, 2024. Verfasst von Ishtiaq Ahmad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mardan Medical complex, Bacha Khan Medical College, Mardan, Pakistan. Hauptthemen laut MEDLINE: Dexamethasone, Cytokine Release Syndrome, Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current study was planned to explore the potential synergistic role of the co-administration of sarilumab and dexamethasone in reducing blood biomarkers associated with cytokine release syndrome in hospitalised patients of coronavirus disease-2019. The sample comprised 22 patients hospitalised with severe and critical severity levels and who were treated with sarilumab and dexamethasone. Positive responses were seen in blood biomarkers, including decreased interleukin-6 alpha levels and improved oxygen saturation. Tumour necrosis factor, D-dimer, C-reactive protein, ferritin and lymphocyte count also showed positive responses in patients who survived than those who died. Lactate dehydrogenase levels fluctuated with improvement among the survivors, but had limited effectiveness in those who died. The findings suggested promising avenues for future treatment strategies in patients with severe coronavirus disease-2019 and cytokine release syndrome. Key Words: Sarilumab, Dexamethasone, Biomarkers, Cytokine release syndrome, COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneCytokine Release SyndromeAntibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentBiomarkersCOVID-19SARS-CoV-2FerritinsC-Reactive ProteinHumansMaleFemaleMiddle AgedInterleukin-6Drug Therapy, CombinationTumor Necrosis Factor-alphaLymphocyte CountL-Lactate DehydrogenaseAdultAgedFibrin Fibrinogen Degradation ProductsHospitalization

Stichwörter der Autor:innen

Sarilumab, Dexamethasone, Biomarkers, Cytokine release syndrome, COVID-19.

Substanzen

DexamethasoneAntibodies, Monoclonal, HumanizedBiomarkerssarilumabFerritinsC-Reactive ProteinInterleukin-6Tumor Necrosis Factor-alphaL-Lactate DehydrogenaseFibrin Fibrinogen Degradation Products

Autor:innen und Institutionen

  • Department of Medicine, Mardan Medical complex, Bacha Khan Medical College, Mardan, Pakistan.

Zitieren

APA

Ahmad, I., & Hamidullah (2024). Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.10480

Vancouver

Ahmad I, Hamidullah. Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients. Journal of the Pakistan Medical Association. 2024. doi:10.47391/jpma.10480

BibTeX
@article{Ahmad2024,
  author = {Ahmad, Ishtiaq and Hamidullah, Hamidullah},
  title = {Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients},
  journal = {Journal of the Pakistan Medical Association},
  year = {2024},
  doi = {10.47391/jpma.10480}
}
Kostenlos starten →